Publication: Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
No Thumbnail Available
Identifiers
Date
2018-04-02
Authors
Díez-Campelo, María
Lorenzo, Jose I
Itzykson, Raphael
Rojas, Silvia M
Berthon, Céline
Luño, Elisa
Beyne-Rauzy, Odile
Perez-Oteyza, Jaime
Vey, Norbert
Bargay, Joan
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P
Description
MeSH Terms
Aged
Azacitidine
Chromosome Aberrations
Chromosomes, Human, Pair 7
Disease-Free Survival
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes
Registries
Retrospective Studies
Risk Factors
Survival Rate
Azacitidine
Chromosome Aberrations
Chromosomes, Human, Pair 7
Disease-Free Survival
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes
Registries
Retrospective Studies
Risk Factors
Survival Rate
DeCS Terms
CIE Terms
Keywords
azacitidine, chromosome 7 abnormalities, high risk MDS, time-dependent analysis